Floridian Neuroscience Institute Inc — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,686,785	350
2024	Research	$273,035	118
2023	Research	$1,367,980	157

Breakdown

Who paid Research payments · program years 2023–2025

Teva Pharmaceuticals USA, Inc. $1,610,853 196 payments
ITI, Inc. $1,222,504 301 payments
Vanda Pharmaceuticals Inc. $248,537 7 payments
ACADIA Pharmaceuticals Inc $185,276 44 payments
Neurocrine Biosciences, Inc. $46,730 75 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $13,900 2 payments

Studies the money was for Research payments · program years 2023–2025

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $1,610,853 196 payments
Iti-007-452 $1,222,504 301 payments
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder $248,537 7 payments
Acp-204-006 $174,168 40 payments
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia $46,730 75 payments
Acp-204-008 $11,108 4 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia $10,400 1 payment
Amulticenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Armstudy Toassess Theefficacy,Safety, Andtolerability of Avp-786 (Deudextromethorphanhydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for Thetreatment Ofnegativesymptoms Ofschizophrenia $3,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.